FMP
Intercept Pharmaceuticals, Inc.
ICPT
NASDAQ
Inactive Equity
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.
19 USD
0.04 (0.211%)
About
ceo
Mr. Jerome B. Durso
sector
Healthcare
industry
Biotechnology
website
https://www.interceptpharma.com
exchange
NASDAQ
Description
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United State...
CIK
0001270073
ISIN
US45845P1084
CUSIP
45845P108
Address
10 Hudson Yards
Phone
646 747 1000
Country
US
Employee
341
IPO Date
Oct 11, 2012
Summary
CIK
0001270073
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
45845P108
ISIN
US45845P1084
Country
US
Price
19
Beta
0.88
Volume Avg.
2.05M
Market Cap
794.69M
Shares
-
52-Week
8.82-21.86
DCF
17.52
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-17.43
P/B
-
Website
https://www.interceptpharma.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ICPT News
It looks like there's no news available.
